Skip to content
DataLookout
Menu

NCT06939595

A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer

StatusActive, Not Recruiting
PhasePhase 3
SponsorCelltrion
Primary completion (estimated)

At risk: Primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified
    • Eligibility criteria expanded, about 5 words
    • Site details revised
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 606 to confirmed 225
    • Site details revised
    v2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence and severity of treatment-emergent adverse events (TEAEs) in the safety set
Timeframe: 12 months after the first dose of the last enrolled patient

Arms and interventions

CT-P51Experimental
EU-approved KeytrudaActive comparator

Drugs: CT-P51, EU-approved Keytruda

Sites

1 site in 1 country

  • ltd "Institute of Clinical Oncology"Tbilisi, Georgia